PRKN and gastric cancer: In addition, our study demonstrates the potential of NR4A1 as a novel drug target for killing NDTMM type cancer cells by inhibiting JNK/parkin-dependent mitophagy, making GC cells more susceptible to TNF-induced apoptosis.